NDAINTRAVENOUSEMULSION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
APONVIE (aprepitant) by Heron Therapeutics is neurokinin 1 antagonists [moa]. Approved for chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting. First approved in 2022.
Drug data last refreshed 19h ago
Mechanism of Action
Neurokinin 1 Antagonists
Pharmacologic Class:
Substance P/Neurokinin-1 Receptor Antagonist
Worked on APONVIE at Heron Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.